Beijing, China, September 1, 2023 – Recently, ROBO Medical's digestive endoscopic surgery robot (EndoFaster), which has complete independent intellectual property rights, completed all enrollment in a prospective, multi-center, parallel controlled clinical trial for registration in China.
EndoFaster digestive endoscopic surgery robot
EndoFaster digestive endoscopic surgery robot system is one of the world's leading endoscopic surgery robots, and it is also the world's first digestive endoscopic surgery auxiliary operating system to complete human registered clinical trials.
The conclusion of this clinical trial enrollment marks an important step in ROBO Medical's process to obtain the National Medical Products Administration (NMPA) registration certificate. Through this clinical trial, the safety and clinical effect of ROBO Medical's EndoFaster digestive endoscopic surgery robot system has been fully verified and recognized, laying a solid foundation for its further development and application.
About ROBO Medical
ROBO Medical is a medical robot R&D enterprise entering the industrialization stage. ROBO Medical was first founded in Switzerland, then branched out to Silicon Valley, USA. Today, ROBO Medical headquarters is based in Shenzhen, China. In the company's fledging days, its technology and talents came from primarily Lausanne Institute of Technology (EPFL) and Harbin Institute of Technology (HIT) alumni. Since then, however, ROBO Medical has grown tremendously, and has brought many of its own technological advancements and talents into the field of medical robots, notably in design and control of Parallel Mechanism, parallel surgical robots, force feedback, machine vision, automatic surgery, and other fields. ROBO Medical has taken the lead in applying these technologies in cardiovascular, anesthesia, digestion, ultrasound diagnosis, etc.
Source: ROBO Medical
Comments